Veracyte, Inc.

Good afternoon, ladies and gentlemen, and welcome to Verisight's first quarter 2021 financial results conference call. As a reminder, today's conference call is being recorded. I'd now like to turn the conference over to Tracy Morris, Verisight's Vice President of Corporate Communications and Investor Relations. You may begin.

Thank you, Mika. Good afternoon, everyone, and thanks for joining us today for a discussion of our first quarter 2021 financial results. With me today are Bonnie Anderson, Verisite's Chairman and Chief Executive Officer, and Jane Alley, our Acting Chief Financial Officer. We're also fortunate to have our incoming Chief Executive Officer, Mark Stapley, on the call. Before we begin, I'd like to remind you that various statements that we may make during this call will include forward-looking statements as defined under applicable securities laws. Forward-looking statements include those regarding the transition of our Chief Executive Officer role and our projections for full year 2021 financial performance. as well as our future plans, prospects, and strategies, financial goals, product attributes, launch plans and pipeline, drivers of growth, expectations regarding reimbursement, and other statements that are not historical fact. It also includes statements regarding the potential impacts to our business resulting from the COVID-19 pandemic, anticipated timing of the launches of new products, availability of our tests internationally, and our total addressable markets. Management's assumptions, expectations, and opinions reflected in these forward-looking statements are subject to risks and uncertainties that may cause actual results and or performance to differ materially from any future results, performance, or achievements discussed in or implied by such forward-looking statements. And the company can give no assurance that they will prove to be correct and will not provide any further guidance or updates on our performance during the quarter unless we do so in a public forum. Please refer to the company's press releases dated May 10, 2021, and the risk factors included in the company's filings with the Securities and Exchange Commission for discussion of important factors that may cause actual events or results to differ materially from those contained in our forward-looking statements. Prior to this call, we published releases announcing our first quarter 2021 results and the execution of our CEO succession plan, through which Bonnie Anderson, our current Chairman and Chief Executive Officer, will assume the role of Executive Chairman, and Mark Staffley will become CEO. Both of these announcements are available on our website at Verisight.com under Press Releases in the Investor Relations section. We also published a business and financial presentation, which we will reference during our remarks. The presentation is also available on our website under Events and Presentations in the Investor Relations section. I will now turn the call over to Bonnie Anderson, Verisight's Chairman and CEO. Bonnie Anderson

Thanks, Tracy, and thanks, everyone, for joining us today. Before we get into the strong progress we made in the first quarter, I will begin with the CEO succession plan that we announced a few minutes ago. I'm delighted to introduce Mark Stapley as Verisight's new Chief Executive Officer to Succeed Me, effective June 1, at which point I will transition to the active role of Executive Chairman of the Board. As a founding CEO who has invested so much into Verisight, I couldn't be happier with the timing and circumstances of this leadership succession. First, the Board and I are extremely pleased that Mark will be taking the reins as CEO of Verisight. He is the right leader with the right experience to take over at this important stage in Verisight's growth. Mark shares my vision for Verisight and is aligned with our mission of applying the power of genomic science and technology to best serve patients by asking the right questions and providing answers that give a clear path forward. He is a seasoned global executive with highly relevant industry experience from his time at Illumina and Helix. He brings an ideal mix of strategic, operational, and financial acumen combined with a proven track record. Over his career, he has built and led complex global operations, including both centralized labs as well as the instrument and reagent kit business, which aligns with Verisight's strategic growth plan. He also has extensive experience integrating acquisitions. Lastly, I believe Mark will be an excellent cultural fit at Verisight. He is a results-oriented leader with the ability to lead and motivate teams around a culture of high performance and high integrity. Second, we believe that Verisight is well-positioned for success with a powerful strategic global vision, and the table is set to execute on this vision and continue our growth in the $50 billion-plus long-term global market for our genomic diagnostic tests. The company is operating from a position of strength with a strong track record of execution and significant growth opportunities. And third, the succession fits with my timeline for transitioning out of the CEO role, which is something I have been discussing with the board for about a year. I am excited and committed to continue serving the company and to be a trusted advisor to Mark in my new role as an active executive chair. In this role, I will be intimately involved in ongoing strategy and business development. I will be Mark's strongest advocate and ally, and I look forward to partnering with him to guide Verisight to achieve its full potential. On a personal note, I'm grateful to the board, our executive leadership team, and Verisight's employees for their commitment and dedication to our mission and the healthcare providers and patients we serve. It is gratifying that together we have built a global enterprise with market-leading tests that are transforming patient care in a range of cancers and other diseases. I am as optimistic as ever about VeriSight, where we are going, and what we can achieve. And with that, I'm thrilled to have Mark with us on the call today to introduce himself to you directly. Mark, please go ahead.